Skip to main content

Market Overview

Why Did BofA Securities Give Globus Medical A Double Upgrade?

Share:
Why Did BofA Securities Give Globus Medical A Double Upgrade?

Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE: GMED) market share gains in 2022, according to BofA Securities.

The Globus Medical Analyst: Craig Bijou upgraded the rating for Globus Medical from Underperform to Buy, while raising the price target from $55 to $80.

The Globus Medical Thesis: The pullback in the stock over the past month, following reports of the acquisition of NuVasive, Inc. (NASDAQ: NUVA) and on COVID-19 omicron variant concerns, “provides a particularly attractive entry point,” Bijou said in the upgrade note.

The NuVasive acquisition is unlikely, the analyst mentioned. He added, “as we wrote at the time. COVID remains a risk to volume, but believe GMED should outperform peers during any flare-ups as it has over the last two years.”

“We see upside potential to the 10% consensus top-line growth next year as the growing robot installed base, increased utilization and new enabling tech products should further drive implant pull through and disposable/service revenue,” Bijou further wrote.

GMED Price Action: Shares of Globus Medical had risen by 2.37% to $69.56 at the time of publication Monday morning.

Photo by National Cancer Institute on Unsplash

Latest Ratings for GMED

DateFirmActionFromTo
Feb 2022Morgan StanleyMaintainsEqual-Weight
Feb 2022Credit SuisseMaintainsOutperform
Feb 2022NeedhamMaintainsBuy

View More Analyst Ratings for GMED

View the Latest Analyst Ratings

 

Related Articles (GMED)

View Comments and Join the Discussion!

Posted-In: BofA SecuritiesAnalyst Color News Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com